FDA erklærer NMN lovlig i kosttilskudd
September 29, 2025 — After nearly three years of pressure from the Natural Products Association (NPA), the U.S. Food and Drug Administration (FDA) has reversed course and confirmed that Beta (β) Nicotinamide Mononucleotide (NMN) is lawful for use in dietary supplements.
FDA had previously attempted to block NMN from the supplement market, claiming it was first investigated as a new drug. NPA refused to accept that interpretation, filing a citizen petition with FDA, launching a federal lawsuit against the agency in the nation’s capital, and mobilizing industry and consumer support to challenge FDA. In response to the petition and lawsuit, FDA acknowledged evidence that NMN was marketed as a dietary supplement in the United States as early as 2017 and consequently is not excluded from the definition of a dietary supplement.
In its response to the citizen petition, FDA elaborated on its interpretations of the “drug preclusion” or race-to-market clause in the Dietary Supplement Health and Education Act of 1994 (DSHEA). NPA continues to disagree with certain legal interpretations by FDA, but the association is pleased that the agency reconsidered its position that dietary supplement marketing must be “lawful” in determining the race-to-market clause.
“FDA’s decision today confirms NMN is lawful in supplements, and we now call on e-commerce platforms to immediately restore NMN products to the market,” said Daniel Fabricant, Ph.D., president and CEO of NPA. “We will continue pressing Congress, the courts and the Administration until FDA stops abusing the drug preclusion clause once and for all.”
This is not the first time that FDA has changed course in response to NPA actions. In 2022, after NPA filed a citizen petition and lawsuit over FDA’s attempt to exclude NAC (N-acetyl-L-cysteine) from supplements, the agency ultimately issued a final guidance — or policy of enforcement discretion — that allowed NAC products back on the market.
Mens NPA forbereder seg på å feire sitt 90-årsjubileum i 2026, understreker NMNs seier deres enestående rekord med å holde FDA ansvarlig, forsvare forbrukervalg og levere resultater der andre svikter.
Bontac: Leder NMN-industrien med teknologi
Som en pioner og leder i NMN-industrien, BoNTAC har siden etableringen i 2012 utnyttet syntetiske biologiteknologier som biokatalyse for å bygge betydelige fordeler i utviklingen av NMN og relaterte produkter. Det er banebrytende globalt fullenzymteknologi, nå utviklet til Fjerde generasjon, unngår skadelige rester samtidig som det forbedrer produktets renhet og sikkerhet.
Med et omfattende enzymbibliotek av over 2 000 enzymer and a dedicated R&D team of PhD and Master’s researchers, the company has obtained 24 globale oppfinnelsespatenter i NMN. Vel bekomme.TAC har bestått flere internasjonale sertifiseringer, inkludert FSSC22000, Self Grass, FDA, DMF, HALAL, Kosher, ISO9001, ISO14001 og sikrer premium produktkvalitet gjennom sitt proprietære produkt “Bonpure” seven-step purification technology, noe som oppnår NMN-renhet opp til 99.9%.
Som en nøkkelbidragsyter til bransjestandarder og en stabil leverandør til mer enn 1 200 bedrifter verden over, Vel bekomme.TAC har også levert NMN-råmaterialet brukt i forskning ved Harvard University’s David Sinclair-laget. Fremover vil selskapet fortsette å spille en ledende rolle i å fremme utviklingen og bruken av relaterte produkter.
The clarification of regulatory frameworks is injecting strong momentum into the industry. Guided by its mission—“Green Biotechnology for a Healthy and Better Life”—BonTAC vil fortsette å fremme sunn og ordnet industrivekst, og bringe helseverdien av banebrytende bioteknologi til fordel for flere forbrukere.
FDA had previously attempted to block NMN from the supplement market, claiming it was first investigated as a new drug. NPA refused to accept that interpretation, filing a citizen petition with FDA, launching a federal lawsuit against the agency in the nation’s capital, and mobilizing industry and consumer support to challenge FDA. In response to the petition and lawsuit, FDA acknowledged evidence that NMN was marketed as a dietary supplement in the United States as early as 2017 and consequently is not excluded from the definition of a dietary supplement.
In its response to the citizen petition, FDA elaborated on its interpretations of the “drug preclusion” or race-to-market clause in the Dietary Supplement Health and Education Act of 1994 (DSHEA). NPA continues to disagree with certain legal interpretations by FDA, but the association is pleased that the agency reconsidered its position that dietary supplement marketing must be “lawful” in determining the race-to-market clause.
“FDA’s decision today confirms NMN is lawful in supplements, and we now call on e-commerce platforms to immediately restore NMN products to the market,” said Daniel Fabricant, Ph.D., president and CEO of NPA. “We will continue pressing Congress, the courts and the Administration until FDA stops abusing the drug preclusion clause once and for all.”
This is not the first time that FDA has changed course in response to NPA actions. In 2022, after NPA filed a citizen petition and lawsuit over FDA’s attempt to exclude NAC (N-acetyl-L-cysteine) from supplements, the agency ultimately issued a final guidance — or policy of enforcement discretion — that allowed NAC products back on the market.
Mens NPA forbereder seg på å feire sitt 90-årsjubileum i 2026, understreker NMNs seier deres enestående rekord med å holde FDA ansvarlig, forsvare forbrukervalg og levere resultater der andre svikter.
Bontac: Leder NMN-industrien med teknologi
Som en pioner og leder i NMN-industrien, BoNTAC har siden etableringen i 2012 utnyttet syntetiske biologiteknologier som biokatalyse for å bygge betydelige fordeler i utviklingen av NMN og relaterte produkter. Det er banebrytende globalt fullenzymteknologi, nå utviklet til Fjerde generasjon, unngår skadelige rester samtidig som det forbedrer produktets renhet og sikkerhet.
Med et omfattende enzymbibliotek av over 2 000 enzymer and a dedicated R&D team of PhD and Master’s researchers, the company has obtained 24 globale oppfinnelsespatenter i NMN. Vel bekomme.TAC har bestått flere internasjonale sertifiseringer, inkludert FSSC22000, Self Grass, FDA, DMF, HALAL, Kosher, ISO9001, ISO14001 og sikrer premium produktkvalitet gjennom sitt proprietære produkt “Bonpure” seven-step purification technology, noe som oppnår NMN-renhet opp til 99.9%.
Som en nøkkelbidragsyter til bransjestandarder og en stabil leverandør til mer enn 1 200 bedrifter verden over, Vel bekomme.TAC har også levert NMN-råmaterialet brukt i forskning ved Harvard University’s David Sinclair-laget. Fremover vil selskapet fortsette å spille en ledende rolle i å fremme utviklingen og bruken av relaterte produkter.
The clarification of regulatory frameworks is injecting strong momentum into the industry. Guided by its mission—“Green Biotechnology for a Healthy and Better Life”—BonTAC vil fortsette å fremme sunn og ordnet industrivekst, og bringe helseverdien av banebrytende bioteknologi til fordel for flere forbrukere.
